Miniature-sized insulin pump now compatible with two CGM systems
Click Here to Manage Email Alerts
Key takeaways:
- The Tandem Mobi automated insulin delivery system can be integrated with Dexcom G7 and G6 CGM systems.
- Instructions on how to install a software update will be sent to current Mobi users in the coming weeks.
A miniature-sized automated insulin delivery system cleared by the FDA in 2023 is now compatible with a new-generation continuous glucose monitor, according to a press release.
As Healio previously reported, the Tandem Mobi insulin pump received FDA clearance for adults and children aged 6 years and older with diabetes in July 2023. The device, which is less than half the size of Tandem’s t:slim X2 insulin pump, is now compatible with both the Dexcom G7 and G6 CGM systems. The new compatibility comes after the t:slim X2 insulin pump was integrated with the Dexcom G7 CGM in late 2023.
When the Tandem Mobi and Dexcom G7 or G6 are integrated, Control-IQ technology will allow the Mobi to connect with the CGM to predict glucose levels 30 minutes in advance and automatically adjust insulin if needed to prevent hyperglycemia and hypoglycemia, according to the release.
“Choice is a hallmark of our offerings, and we’ve proven this commitment with the expansion of our insulin pump portfolio and extended CGM compatibilities,” John Sheridan, president and CEO of Tandem Diabetes Care, said in a press release. “With this integration, we’re providing more flexibility for our customers and continuing our decade-long partnership with Dexcom to bring innovative and discrete solutions to people living with diabetes.”
Users of the Mobi in the U.S. will receive an email in the coming weeks when their software update is ready with instructions on how to add the new compatibility feature. Updated software will be preloaded for new Mobi users.
Click Here to Manage Email Alerts